Organon & Co (NYSE:OGN)
$ 15.06 0.11 (0.74%) Market Cap: 3.85 Bil Enterprise Value: 11.78 Bil PE Ratio: 2.97 PB Ratio: 7.81 GF Score: 71/100

Organon & Co at Piper Sandler Healthcare Conference Transcript

Nov 29, 2023 / 04:00PM GMT
Release Date Price: $11.41 (+0.97%)
David A. Amsellem
Piper Sandler & Co., Research Division - MD & Senior Research Analyst

Okay. Good morning, everyone, and let's get started. Welcome again to the 35th Annual Piper Sandler Healthcare Conference. I'm David Amsellem from the pharma team. And with us is Organon. We have Kevin Ali, CEO; and Matt Walsh, CFO. Thanks gentlemen, for joining us. And certainly, lots to talk about, so I'm going to dive right in with questions here.

Kevin Ali
Organon & Co. - CEO & Director

Go ahead.

Questions & Answers

David A. Amsellem
Piper Sandler & Co., Research Division - MD & Senior Research Analyst

So I'll start at a high level and ask how you're thinking about balancing debt paydown and capital deployment to bolster the pipeline and/or commercial portfolio. So maybe I'll start with you, Kevin.

Kevin Ali;David A. Amsellem
Organon & Co. - CEO & Director;Piper

You jumping right in the deep end first?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot